Clinical study of thalidomide response in spondyloarthropathy patients
Not Applicable
- Conditions
- Health Condition 1: M45-M49- Spondylopathies
- Registration Number
- CTRI/2021/08/035852
- Lead Sponsor
- INSTITUTE OF MEDICAL SCIENCE BH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient of spondyloathropathy according to ASAS criteria
Above 16 years of age
Able to give informed consent
Exclusion Criteria
Chronic illness(TB,Hematologic malignacies ,cardiac disease )that interfere with crp and esr measurements.
Mechanical back pain
Diagnosed case of peripheral neuropathy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective change in form of basdai change and crp and esr measurementsTimepoint: 6 months
- Secondary Outcome Measures
Name Time Method Patient requiring change of therapyTimepoint: 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie thalidomide's anti-inflammatory effects in spondyloarthropathy patients?
How does thalidomide compare to TNF-α inhibitors in managing axial spondyloarthritis symptoms?
Which biomarkers correlate with thalidomide response in seronegative arthritis subtypes?
What are the long-term adverse events of thalidomide in spondylopathies and management strategies?
Are there synergistic effects combining thalidomide with IL-17 inhibitors for spondyloarthropathy?